Last reviewed · How we verify

Hereditary factor VIII deficiency disease — Treatment Landscape & Competitive Intelligence

Hereditary factor VIII deficiency disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hereditary factor VIII deficiency disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Hemlibra EMICIZUMAB Roche Coagulation factor IX 2017-01-01
Afstyla LONOCTOCOG ALFA CSL Behring GmbH 2017-01-01
Elocta EFMOROCTOCOG ALFA Swedish Orphan Biovitrum AB 2015-01-01
Nuwiq SIMOCTOCOG ALFA Octapharma AB 2014-01-01
Novoeight TUROCTOCOG ALFA Novo Nordisk 2013-01-01
Refacto Af MOROCTOCOG ALFA Pfizer Ltd 1999-01-01
Eptacog Alfa EPTACOG ALFA (ACTIVATED) Novo Nordisk 1996-01-01
Ddavp DESMOPRESSIN Ferring Pharms Inc Factor VIII Activator Vasopressin V1b receptor 1978-01-01
Argipressin Argipressin Kristina Svennerholm Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor
Esperoct Esperoct Novo Nordisk A/S

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Novo Nordisk · 2 drugs in Hereditary factor VIII deficiency disease
  2. CSL Behring GmbH · 1 drug in Hereditary factor VIII deficiency disease
  3. Emory University · 1 drug in Hereditary factor VIII deficiency disease
  4. Ferring Pharms Inc · 1 drug in Hereditary factor VIII deficiency disease
  5. Hormozgan University of Medical Sciences · 1 drug in Hereditary factor VIII deficiency disease
  6. Kristina Svennerholm · 1 drug in Hereditary factor VIII deficiency disease
  7. Novo Nordisk A/S · 1 drug in Hereditary factor VIII deficiency disease
  8. Octapharma AB · 1 drug in Hereditary factor VIII deficiency disease
  9. Pfizer Ltd · 1 drug in Hereditary factor VIII deficiency disease
  10. Roche · 1 drug in Hereditary factor VIII deficiency disease
  11. Swedish Orphan Biovitrum AB · 1 drug in Hereditary factor VIII deficiency disease
  12. · 1 drug in Hereditary factor VIII deficiency disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hereditary factor VIII deficiency disease:

Cite this brief

Drug Landscape (2026). Hereditary factor VIII deficiency disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hereditary-factor-viii-deficiency-disease. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing